Related Experiment Video

Updated: Aug 17, 2026

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Beneficial effect of phlebotomy on hepatitis C virus-associated musculoskeletal manifestations

N Hilzenrat1, D Buskila, D Zilberman

  • 1Department of Medicine B, Soroka Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Clinical Rheumatology
|November 7, 1998
PubMed

Insights

Chronic hepatitis C virus (HCV) infection can cause rheumatic issues. Reducing iron levels through phlebotomy improved symptoms in two patients, suggesting a link between iron overload and HCV-related rheumatic complications.

Area of Science:

  • Hepatology
  • Rheumatology
  • Iron Metabolism

Background:

  • Chronic hepatitis C virus (HCV) infection is linked to extrahepatic manifestations.
  • An association between iron overload and chronic HCV infection is increasingly recognized.
  • The impact of iron reduction therapy on HCV-related extrahepatic symptoms remains unclear.

Observation:

  • Two patients with chronic HCV infection presented with severe rheumatic symptoms: myalgia and seronegative nonerosive symmetrical polyarthritis.
  • Conventional anti-inflammatory and second-line treatments provided minimal relief.
  • Recurrent phlebotomy (blood removal) led to significant symptom improvement.

Findings:

  • The study observed a notable improvement in rheumatic symptoms following phlebotomy in HCV-infected patients.
  • This suggests a potential role for iron overload in the development of rheumatic complications associated with HCV.

Implications:

  • Iron reduction therapy, such as phlebotomy, may be a viable therapeutic strategy for managing rheumatic manifestations in chronic HCV.
  • Further research is warranted to elucidate the precise mechanisms linking iron overload, HCV, and rheumatic disease.
  • These findings could lead to novel treatment approaches for extrahepatic manifestations of HCV infection.

More Related Videos

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...